Your browser is no longer supported. Please, upgrade your browser.
Clene Inc.
Index- P/E- EPS (ttm)-1.53 Insider Own3.20% Shs Outstand60.67M Perf Week5.52%
Market Cap493.24M Forward P/E- EPS next Y-0.70 Insider Trans16.92% Shs Float18.16M Perf Month-16.03%
Income-55.10M PEG- EPS next Q-0.15 Inst Own4.40% Short Float7.87% Perf Quarter-0.45%
Sales0.30M P/S1644.13 EPS this Y-415.20% Inst Trans5.38% Short Ratio3.04 Perf Half Y-33.38%
Book/sh-0.59 P/B- EPS next Y38.10% ROA- Target Price- Perf Year-17.14%
Cash/sh0.86 P/C10.28 EPS next 5Y- ROE- 52W Range6.23 - 17.82 Perf YTD-2.33%
Dividend- P/FCF- EPS past 5Y- ROI-783.70% 52W High-50.62% Beta-
Dividend %- Quick Ratio13.00 Sales past 5Y- Gross Margin30.40% 52W Low41.25% ATR1.04
Employees63 Current Ratio13.10 Sales Q/Q100.00% Oper. Margin- RSI (14)45.18 Volatility7.49% 14.54%
OptionableNo Debt/Eq- EPS Q/Q-188.60% Profit Margin- Rel Volume0.40 Prev Close8.28
ShortableYes LT Debt/Eq- EarningsMay 11 BMO Payout- Avg Volume470.64K Price8.80
Recom2.00 SMA20-6.88% SMA50-15.17% SMA200-17.61% Volume190,027 Change6.28%
Aug-03-21 07:00AM  
Jun-30-21 07:00AM  
Jun-28-21 07:00AM  
Jun-15-21 07:00AM  
May-26-21 11:06AM  
May-24-21 08:00AM  
May-19-21 09:00AM  
May-17-21 07:00AM  
May-12-21 09:00AM  
May-11-21 07:00AM  
Apr-30-21 07:00AM  
Mar-31-21 03:04AM  
Mar-29-21 07:00AM  
Mar-10-21 09:00AM  
Mar-09-21 08:32AM  
Mar-03-21 04:05PM  
Mar-01-21 07:00AM  
Feb-25-21 07:31AM  
Feb-19-21 07:00AM  
Feb-16-21 07:00AM  
Jan-19-21 07:00AM  
Dec-30-20 05:38PM  
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mosca AlisonDirectorMay 24Buy9.6351,921499,99951,921May 24 06:59 PM
MATLIN DAVID JDirectorMay 24Buy9.63207,6841,999,9971,378,897May 24 04:24 PM